Transgene and Tasly JV Starts Operations with Four Transgene Molecules

The JV established by France’s Transgene and Tasly Pharma of China announced that Transgene is contributing China rights to four biotech immunotherapeutic candidates to the JV. The JV will be capitalized with $3.2 million from Transgene and $6.6 million from Tasly. The value of Transgene’s drug IP evens its investment in the 50:50 partnership with Tasly’s. Transgene develops immunotherapeutic products aimed at cancer and infectious diseases. More details.... Stock Symbols: (Euronext: TNG) (SHA: 600535) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});